<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973478</url>
  </required_header>
  <id_info>
    <org_study_id>35RC08_8902</org_study_id>
    <nct_id>NCT01973478</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression</brief_title>
  <acronym>STHYM</acronym>
  <official_title>Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorders are real public health issues in terms of diagnosis and treatment.&#xD;
      Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide&#xD;
      risk is important.&#xD;
&#xD;
      Patients with TRD are potential candidates for neurosurgical interventions to treat&#xD;
      depression. However, psychosurgery interventions based upon lesions, showed their limitations&#xD;
      related to 1. the large variability in neurosurgical gestures, 2. their side effects, and of&#xD;
      course 3. the irreversible damage caused by the surgery.&#xD;
&#xD;
      Thus, deep brain stimulation (DBS) could represent an opportunity for patients suffering from&#xD;
      TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed&#xD;
      encouraging results. The investigators have thus planned a randomized controlled trial versus&#xD;
      sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because of their recurrent nature, their prevalence and their consequences, major depressive&#xD;
      disorders are real public health issues in terms of diagnosis and treatment.&#xD;
&#xD;
      Some forms of depression are chronic and resistant to treatment (TRD), either unipolar&#xD;
      (repeated episodes of depression) or bipolar (repeated episodes of depression and manic&#xD;
      and/or hypomanic episodes). In these forms suicide risk is important.&#xD;
&#xD;
      Patients with TRD are potential candidates for neurosurgical interventions to treat&#xD;
      depression. The benefit of neurosurgical procedures is expected to be important in these&#xD;
      patients.&#xD;
&#xD;
      Psychosurgery interventions based upon lesions, however, showed their limitations related to&#xD;
      1/ the large variability in neurosurgical gestures, 2/ their side effects, and of course 3/&#xD;
      the irreversible damage caused by the surgery.&#xD;
&#xD;
      Current brain imaging data yielded fresh information about the pathophysiology of depression&#xD;
      and suggested new therapeutic approaches in TRD.&#xD;
&#xD;
      Modulation of sub-caudate specific pathways, which are part of orbitofrontal and anterior&#xD;
      cingulate cortico-subcortical loops should allow for a diminution of depressive symptoms.&#xD;
&#xD;
      The modulation of these specific pathways, initially targeted by classical neurosurgery,&#xD;
      could benefit from current developments in functional neurosurgery.&#xD;
&#xD;
      Deep brain stimulation (DBS) may represent an opportunity for patients suffering from TRD.&#xD;
      Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging&#xD;
      results. The investigators have thus planned a randomized controlled trial versus sham&#xD;
      stimulation to confirm the therapeutic value of nucleus accumbens DBS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2014</start_date>
  <completion_date type="Actual">November 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)</measure>
    <time_frame>Month 7</time_frame>
    <description>Response is defined as a 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission (yes/no)</measure>
    <time_frame>Month 7</time_frame>
    <description>Remission is defined as an HDRS-17 score &lt; 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI (Clinical global impressions) amelioration (yes/no)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score of 1 or 2 (item 2 of the CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAF (Global assessment of functioning)</measure>
    <time_frame>Month 7</time_frame>
    <description>Presence of a score ≥ 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDRS-17 (Hamilton depression rating scale, 17 items version)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS (Montgomery-Asberg Depression Rating Scale)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI (Beck Depression Inventory)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI (Clinical global impressions)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LARS (Lille Apathy Rating scale)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAF (Global assessment of functioning)</measure>
    <time_frame>Month 7</time_frame>
    <description>Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment</measure>
    <time_frame>Day -7 ; Month 1; Month 7; Month 13; Month 19; Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral metabolism (PET scans)</measure>
    <time_frame>Day -7; Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Month 24</time_frame>
    <description>Adverse events occuring during the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HDRS-17 (Hamilton depression rating scale, 17 items version)</measure>
    <time_frame>Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>MADRS (Montgomery-Asberg Depression Rating Scale)</measure>
    <time_frame>Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>BDI (Beck Depression Inventory)</measure>
    <time_frame>Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>CGI (Clinical global impressions)</measure>
    <time_frame>Month -3 ; Month -1; Day-7; Day15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>LARS (Lille Apathy Rating scale)</measure>
    <time_frame>Day -7; Month 1; Month 7; Month 13; Month 19; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>GAF (Global assessment of functioning)</measure>
    <time_frame>Month -3 ; Month -1; Day -7; Month 1; Month 7; Month 13; Month 19; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>YMRS (Young Mania Rating Scale)</measure>
    <time_frame>Day -7; Month 1; Month 7; Month 13; Month 19; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>MATHYS (Multidimensional Assessment of Thymic States)</measure>
    <time_frame>Day -7; Month 1; Month 7; Month 13; Month 19; Month 24</time_frame>
    <description>Longitudinal evolution of the score</description>
  </other_outcome>
  <other_outcome>
    <measure>Response (50 % decrease of the HDRS-17)</measure>
    <time_frame>Month 24</time_frame>
    <description>During the whole follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Remission</measure>
    <time_frame>M24</time_frame>
    <description>During the whole follow up Remission is defined as an HDRS-17 score &lt; 7</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Recurrent Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The medical device includes:&#xD;
Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)&#xD;
Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.&#xD;
The target is the Accumbens nucleus.&#xD;
The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.&#xD;
The DBS is &quot;on&quot; during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The medical device includes:&#xD;
Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)&#xD;
Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.&#xD;
The target is the Accumbens nucleus.&#xD;
The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.&#xD;
The DBS is &quot;off&quot; during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS</intervention_name>
    <arm_group_label>DBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM</intervention_name>
    <arm_group_label>SHAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  DSM-IV (DSM = Diagnostic and Statistical Manual) criteria for a recurrent depressive&#xD;
             disorder or bipolar disorder&#xD;
&#xD;
          -  Duration of the episode &gt; 2 years&#xD;
&#xD;
          -  Severity of the episode attested by :&#xD;
&#xD;
               -  A HDRS score &gt; 21&#xD;
&#xD;
               -  A CGI score ≥ 4&#xD;
&#xD;
               -  A GAF &lt; 50&#xD;
&#xD;
          -  Persistence of severity criteria during the screening&#xD;
&#xD;
          -  Following characteristics resistance in case of recurrent depressive disorder :&#xD;
&#xD;
               -  Stage V of the classification of Thase and Rush&#xD;
&#xD;
               -  Unsuccessful treatment by the association of two antidepressants (or&#xD;
                  intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by the association for at least 6 weeks of one of the&#xD;
                  following treatments : lithium , thyroid hormone , buspirone , pindolol with an&#xD;
                  antidepressant (or intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by the combination of a second-generation antipsychotic&#xD;
                  (olanzapine, risperidone, amisulpride, aripiprazole, clozapine and quetiapine) to&#xD;
                  an antidepressant (or intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by a structured psychotherapy&#xD;
&#xD;
          -  Following characteristics of resistance in case of bipolar disorder:&#xD;
&#xD;
               -  Unsuccessful treatment by lithium (or intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by at least one mood stabilizer anticonvulsant (or&#xD;
                  intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by at least one second-generation antipsychotic (or&#xD;
                  intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by the combination of two mood stabilizers with at least&#xD;
                  an anticonvulsant (or intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by electro-convulsive therapy sessions (or&#xD;
                  intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by at least one antidepressant , mood stabilizer&#xD;
                  combination (or intolerance/contra-indications)&#xD;
&#xD;
               -  Unsuccessful treatment by a structured psychotherapy&#xD;
&#xD;
          -  Understanding the conduct of the study&#xD;
&#xD;
          -  Giving a written informed consent&#xD;
&#xD;
          -  Benefiting from the french social insurance&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
          -  Comorbid axis 1 disorder (except dysthymia, generalized anxiety disorder, social&#xD;
             phobia, panic disorder)&#xD;
&#xD;
          -  Alcohol or other psychoactive substances dependence (except nicotine)&#xD;
&#xD;
          -  Suicidal risk during the last month assessed by the MINI (Mini International&#xD;
             Neuropsychiatric Interview), the DIGS (Diagnostic Interview for Genetic Studies) and&#xD;
             the item 3 of the HDRS&#xD;
&#xD;
          -  Suicide attempt in the last 6 months or two suicide attempts in the previous two years&#xD;
&#xD;
          -  History of forensic act or furious mania&#xD;
&#xD;
          -  Depressive episode with congruent or incongruent psychotic features or history of a&#xD;
             depressive episode with psychotic features&#xD;
&#xD;
          -  Comorbid cluster A or B personality disorders according to the DSM IV-TR evaluated&#xD;
             using the SCID2 (Structured Clinical Interview for DSM-IV)&#xD;
&#xD;
          -  Cognitive Impairment (Mattis &lt; 130)&#xD;
&#xD;
          -  MRI (Magnetic Resonance Imaging) contraindication to stimulation or contraindications&#xD;
             for MRI&#xD;
&#xD;
          -  Major somatic disease making it impossible to set up the study treatment&#xD;
&#xD;
          -  Pregnant women, or nursing or childbearing potential without effective contraception&#xD;
&#xD;
          -  Involuntary commitment&#xD;
&#xD;
          -  Guardianship&#xD;
&#xD;
          -  Participation in another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Michel Reymann</last_name>
    <role>Study Chair</role>
    <affiliation>CIC INSERM 0203 CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Naudet</last_name>
    <role>Study Chair</role>
    <affiliation>CIC INSERM 0203 CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Millet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Pitié Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHS</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHS</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Recurrent depressive disorder</keyword>
  <keyword>Bipolar disorder</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Accumbens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

